Seeking Alpha

Sanofi-Aventis (SNY)

()
52wk high:
52wk low:
EPS:
PE:
Dividend:
Yield:
Market Cap:
Exchange:
Analysis - Latest Articles
Cramer
Instablogs
  • Kendle International Healthcare
    Mon November 2, 2009 • Michael Michaud • Comment!
  • H1N1 -- How to buy into the fear
    Tue October 6, 2009 • Jim Van Meerten • Comment!
  • Winners and Losers: Takeover Talk Continues
    Wed September 30, 2009 • M. E. Garza • Comment!
Write a post on SNY | More Instablogs on SNY »
Sentiment
What advice would you give to
SNY?
124 characters left
Market Currents
  • Wednesday 09:42 am Sanofi-Aventis (SNY +0.1%) increases its 2007 biotech deal with Regeneron Pharmaceuticals (REGN +15.1%), boosting its payment for R&D to $160M/year from $100M, and extending the pact by five years, through 2017. REGN chief Dr. Leonard S. Schleifer says the deal is a model of how Big Pharma can collaborate with biotech without suffocating it: "They leave Regeneron and its culture to do its thing." (PR) Comment!
What's your view of SNY?
Make sure you include SNY
140 characters left
More StockTalks on SNY »